Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-12-06 Sale | 2022-12-09 7:38 pm | TherapeuticsMD Inc. | TXMD | Glickman Mark A Co-Chief Executive Officer | 440 | $4.9215 | $2,165 | 4,760 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-06-07 Option Award | 2024-06-07 7:25 pm | N/A N/A | NeuroBo Pharmaceuticals Inc. | NRBO | Glickman Mark A Director | 5,051 | $0 | 9,740 (Direct) | View |
| 2023-07-27 Option Award | 2023-07-28 06:11 am | N/A N/A | NeuroBo Pharmaceuticals Inc. | NRBO | Glickman Mark A Director | 37,500 | $0 | 37,500 (Direct) | View |
| 2022-12-06 Exercise | 2022-12-09 7:38 pm | N/A N/A | TherapeuticsMD Inc. | TXMD | Glickman Mark A Co-Chief Executive Officer | 1,734 | $0 | 4,760 (Direct) | View |
| 2022-03-31 Option Award | 2022-03-31 5:15 pm | N/A N/A | TherapeuticsMD Inc. | TXMD | Glickman Mark A Chief Business Officer | 260,000 | $0 | 260,000 (Direct) | View |
| 2022-03-23 Option Award | 2022-03-28 07:00 am | N/A N/A | TherapeuticsMD Inc. | TXMD | Glickman Mark A Chief Business Officer | 260,000 | $0 | 260,000 (Direct) | View |
| 2021-10-15 Option Award | 2021-10-15 5:20 pm | N/A N/A | TherapeuticsMD Inc. | TXMD | Glickman Mark A Chief Business Officer | 920,000 | $0 | 920,000 (Direct) | View |
| 2020-01-02 Option Award | 2020-01-03 4:27 pm | N/A 2030-01-02 | Esperion Therapeutics Inc. | ESPR | Glickman Mark A Chief Commercial Officer | 32,550 | $0 | 52,550 (Direct) | View |